The Archive
-
Japanese drugmaker urges G7 to fix infectious diseases market -
Japan’s release of radioactive water from Fukushima angers China
-
Japan’s Astellas to buy Iveric Bio for $5.9bn in US biotech deal
-
Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug
